A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer

NCT02058381 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Pre-menopausal Breast Cancer
PI3K Pathway Inhibition

Interventions

DRUG: alpelisib (BYL719)
DRUG: buparlisib (BKM120)

Sponsor

Novartis Pharmaceuticals